The efficacy of combination therapy including an oral gelatinase inhibitor (CT1746) and cytotoxic agent was analyzed using the murine Lewis lung carcinoma model. Primary tumors, pulmonary metastases, and sera from tumor-bearing animals had increased gelatinase B activity that was inhibited by CT1746 levels achievable in vivo. The combination of CT1746 and cyclophosphamide (CTX) was significantly more effective than either single agent in delaying local tumor growth (CT1746/CTX, 30.9 ± 1.7 days; CT1746, 2.6 ± 0.3 days; CTX, 19.5 ± 1.1 days; P < .001) and reducing the number and size of pulmonary metastases [CT1746/CTX, 5 ± 2 (15% metastases > 3 mm); CT1746, 15 ± 4 (55% > 3 mm); CTX, 11 ± 3 (63% > 3 mm); no treatment, 24 ± 5 (62% > 3 mm); P < .001]. These data support the notion of combining matrix metalloproteinase inhibitors and cytotoxic agents to treat certain epithelial malignancies.

This content is only available via PDF.